News & Media
Focal Medical Receives Award from NCI to Develop Treatment for Oral Cavity Cancer
Cary, North Carolina — Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a…
Focal Medical Provides Business Update
Ness Bermingham, Ph.D. Khosla Ventures partner and Intellia Therapeutics founder, joins Board. Advance of IOP…
PRESS RELEASE: Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer
ACT-IOP-003 is an implantable iontophoretic product designed to safely achieve high concentration of gemcitabine in…
Focal Medical Successfully Completes Development of a Laparoscopic Surgical Implantation Technique for Targeted Therapeutic System
Developed a laparoscopic surgical technique to enable the minimally invasive implantation of ACT-IOP-003 device onto…
PRESS RELEASE: Focal Medical Complete Development of a Therapeutic System to Deliver Gemcitabine Directly to the Pancreas
Successful completion of development of a precision therapeutic system designed to safely achieve high concentration…
Initiation of Canine Oral Cancer Study
Trial & Enrollment Details Cary, NC and Roanoke, VA, May 04, 2023 — Focal…
PRESS RELEASE: Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical | Company Launches Corporate Rebranding
RALEIGH, N.C. (November 1, 2022): Focal Medical, Inc. (formerly Advanced Chemotherapy Technologies, Inc.), a privately held,…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial
This investment is in addition to the previously announced Series A investment of $5.5 million…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Announces $5.5M Series A Financing Round led by Khosla Ventures
The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Announces Issuance of US Patent for an Interventional Drug Delivery System
Raleigh, NC, June 30th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Files IND Application for First in Human use of ACT-IOP-003 in Pancreatic Cancer Patients
Raleigh, NC, March 20th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
PRESS RELEASE: Notice of Allowance Received from U.S. Patent and Trademark Office for Patent Application with Claims Covering Combination Iontophoresis and Radiation Therapy
Raleigh, NC, August 30th, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
ACT announces receipt of Phase II NIH grant to support device development and first-in-human clinical trial for implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma
Raleigh, NC, August 22nd, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
Leading the way toward greater hope for pancreatic cancer patients
Tony Voiers joined Advanced Chemotherapy Technologies as CEO after meeting with company co-founder Jen Jen…
NC companies shine at SEBIO Forum
November 18, 2018— Bioscience companies from North Carolina dominated the awards competition at the 20th…
Simulation Optimizes a Chemotherapy Implant to Treat Pancreatic Cancer
There are few illnesses as crafty as pancreatic cancer. It spreads like weeds and resists…
ACT announces receipt of NIH grant to support first in human clinical trial development and execution for an implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma.
Raleigh, NC, September 28th, 2018 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
‘In MedTech History’ – Oncology Device Technology
Fueled by the passion of pioneering physicists, physicians and medtech innovators looking for a way…
UNC Spinout Developing Device for Better Chemo Delivery
Pancreatic cancer is an elusive and deadly disease. It often has no initial symptoms, and…
Focal Medical, Inc.
2301 Stonehenge Drive, Suite 115
Raleigh, NC 27615
Focal Medical Copyright 2022 | Focal Medical is an equal opportunity employer
Terms of service – Privacy policy – Other policies